Ramesh Kumar Marimuthu Ragavan, Arunagirinathan Narasingam, Srivani Seetharaman, Dhanasezhian Aridoss, Vijaykanth Nallusamy, Manikandan Natesan, Balakrishnan Sethuramalingam, Vignesh Ramachandran, Balakrishnan Pachamuthu, Solomon Suniti, Solomon Sunil S
1 Post Graduate and Research Department of Microbiology and Biotechnology, Presidency College (Autonomous) , Chennai, India .
2 Department of Microbiology, Dr. ALM PGIBMS, University of Madras , Chennai, India .
Microb Drug Resist. 2017 Jul;23(5):602-608. doi: 10.1089/mdr.2016.0034. Epub 2016 Nov 17.
The antibiotic, trimethoprim-sulfamethoxazole (TMP-SMX), is generally used for prophylaxis in HIV individuals to protect them from Pneumocystis jiroveci infection. Long-term use of TMP-SMX develops drug resistance among bacteria in HIV patients. The study was aimed to detect the TMP-SMX resistance genes among gram-negative bacteria from HIV patients. TMP-SMX-resistant isolates were detected by the Kirby-Bauer disc diffusion method. While TMP resistance genes such as dfrA1, dfrA5, dfrA7, and dfrA17 and SMX resistance genes such as sul1 and sul2 were detected by multiplex PCR, class 1 and class 2 integrons were detected by standard monoplex PCR. Of the 151 TMP-SMX-resistant bacterial isolates, 3 were positive for sul1 alone, 48 for sul2 alone, 11 for dfrA7 alone, 21 for sul1 and sul2, 1 for sul1 and dfrA7, 23 for sul2 and dfrA7, 2 for sul2 and dfrA5, 41 for sul1, sul2, and dfrA7, and 1 for sul2, dfrA5, and dfrA7. Of 60 TMP-SMX-resistant isolates positive for integrons, 44 had class 1 and 16 had class 2 integrons. It was found that the prevalence of sul genes (n = 202; p < 0.001) was higher compared with dfr genes (n = 80; p < 0.001), and 87.4% (n = 132; p < 0.001) of TMP-SMX-resistant isolates also were positive for β-lactamase production. This type of study is reported for the first time from HIV patients in India. Therefore, this study indicates that dissemination of TMP-SMX resistance genes and class 1 and class 2 integrons along with β-lactamase production among gram-negative bacteria in HIV patients will certainly make their treatment to bacterial infections more complicated in clinical settings.
抗生素复方新诺明(TMP-SMX)通常用于对艾滋病病毒感染者进行预防,以保护他们免受耶氏肺孢子菌感染。长期使用TMP-SMX会使艾滋病病毒患者体内的细菌产生耐药性。该研究旨在检测艾滋病病毒患者革兰氏阴性菌中的TMP-SMX耐药基因。采用 Kirby-Bauer 纸片扩散法检测对TMP-SMX耐药的菌株。通过多重聚合酶链反应(PCR)检测dfrA1、dfrA5、dfrA7和dfrA17等TMP耐药基因以及sul1和sul2等SMX耐药基因,通过标准单重PCR检测1类和2类整合子。在151株对TMP-SMX耐药的细菌分离株中,仅sul1阳性的有3株,仅sul2阳性的有48株,仅dfrA7阳性的有11株,sul1和sul2阳性的有21株,sul1和dfrA7阳性的有1株,sul2和dfrA7阳性的有23株,sul2和dfrA5阳性的有2株,sul1、sul2和dfrA7阳性的有41株,sul2、dfrA5和dfrA7阳性的有1株。在60株整合子阳性的对TMP-SMX耐药的分离株中,44株有1类整合子,16株有2类整合子。研究发现,sul基因(n = 202;p < 0.001)的流行率高于dfr基因(n = 80;p < 0.001),并且87.4%(n = 132;p < 0.001)的对TMP-SMX耐药的分离株β-内酰胺酶产生也呈阳性。印度首次报道了针对艾滋病病毒患者的此类研究。因此,该研究表明,艾滋病病毒患者革兰氏阴性菌中TMP-SMX耐药基因、1类和2类整合子以及β-内酰胺酶产生的传播,肯定会使临床环境中对他们细菌感染的治疗更加复杂。